Literature DB >> 26271599

Assays for therapeutic drug monitoring of β-lactam antibiotics: A structured review.

Mieke Carlier1, Veronique Stove2, Steven C Wallis3, Jan J De Waele4, Alain G Verstraete2, Jeffrey Lipman5, Jason A Roberts6.   

Abstract

In some patient groups, including critically ill patients, the pharmacokinetics of β-lactam antibiotics may be profoundly disturbed due to pathophysiological changes in distribution and elimination. Therapeutic drug monitoring (TDM) is a strategy that may help to optimise dosing. The aim of this review was to identify and analyse the published literature on the methods used for β-lactam quantification in TDM programmes. Sixteen reports described methods for the simultaneous determination of three or more β-lactam antibiotics in plasma/serum. Measurement of these antibiotics, due to low frequency of usage relative to some other tests, is generally limited to in-house chromatographic methods coupled to ultraviolet or mass spectrometric detection. Although many published methods state they are fit for TDM, they are inconvenient because of intensive sample preparation and/or long run times. Ideally, methods used for routine TDM should have a short turnaround time (fast run-time and fast sample preparation), a low limit of quantification and a sufficiently high upper limit of quantification. The published assays included a median of 6 analytes [interquartile range (IQR) 4-10], with meropenem and piperacillin being the most frequently measured β-lactam antibiotics. The median run time was 8 min (IQR 5.9-21.3 min). There is also a growing number of methods measuring free concentrations. An assay that measures antibiotics without any sample preparation would be the next step towards real-time monitoring; no such method is currently available.
Copyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Chromatography; Free concentrations; Immunoassays; Methods of analysis; TDM; Unbound

Mesh:

Substances:

Year:  2015        PMID: 26271599     DOI: 10.1016/j.ijantimicag.2015.06.016

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

1.  Antibiotic prophylaxis with high-dose cefoxitin in bariatric surgery: an observational prospective single center study.

Authors:  Thibaut Belveyre; Philippe Guerci; Elise Pape; Nathalie Thilly; Kossar Hosseini; Laurent Brunaud; Nicolas Gambier; Claude Meistelman; Marie-Reine Losser; Julien Birckener; Julien Scala-Bertola; Emmanuel Novy
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

2.  Simultaneous Determination of Eight β-Lactam Antibiotics, Amoxicillin, Cefazolin, Cefepime, Cefotaxime, Ceftazidime, Cloxacillin, Oxacillin, and Piperacillin, in Human Plasma by Using Ultra-High-Performance Liquid Chromatography with Ultraviolet Detection.

Authors:  Tiphaine Legrand; Dominique Vodovar; Nicolas Tournier; Nihel Khoudour; Anne Hulin
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Gut Bacteria Missing in Severe Acute Malnutrition, Can We Identify Potential Probiotics by Culturomics?

Authors:  Maryam Tidjani Alou; Matthieu Million; Sory I Traore; Donia Mouelhi; Saber Khelaifia; Dipankar Bachar; Aurelia Caputo; Jeremy Delerce; Souleymane Brah; Daouda Alhousseini; Cheikh Sokhna; Catherine Robert; Bouli A Diallo; Aldiouma Diallo; Philippe Parola; Michael Golden; Jean-Christophe Lagier; Didier Raoult
Journal:  Front Microbiol       Date:  2017-05-23       Impact factor: 5.640

4.  Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations.

Authors:  Nynke G L Jager; Reinier M van Hest; Jiao Xie; Gloria Wong; Marta Ulldemolins; Roger J M Brüggemann; Jeffrey Lipman; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

5.  Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing.

Authors:  Véronique Suttels; Pascal André; Yann Thoma; François Veuve; Laurent Decosterd; Benoît Guery; Thierry Buclin
Journal:  JAC Antimicrob Resist       Date:  2022-04-21

6.  Development and evaluation of uncertainty quantifying machine learning models to predict piperacillin plasma concentrations in critically ill patients.

Authors:  Jarne Verhaeghe; Sofie A M Dhaese; Thomas De Corte; David Vander Mijnsbrugge; Heleen Aardema; Jan G Zijlstra; Alain G Verstraete; Veronique Stove; Pieter Colin; Femke Ongenae; Jan J De Waele; Sofie Van Hoecke
Journal:  BMC Med Inform Decis Mak       Date:  2022-08-25       Impact factor: 3.298

7.  Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates.

Authors:  Jennifer Le; Brenda Poindexter; Janice E Sullivan; Matthew Laughon; Paula Delmore; Martha Blackford; Ram Yogev; Laura P James; Chiara Melloni; Barrie Harper; Jeff Mitchell; Daniel K Benjamin; Felix Boakye-Agyeman; Michael Cohen-Wolkowiez
Journal:  Ther Drug Monit       Date:  2018-02       Impact factor: 3.118

Review 8.  Delivering precision antimicrobial therapy through closed-loop control systems.

Authors:  T M Rawson; D O'Hare; P Herrero; S Sharma; L S P Moore; E de Barra; J A Roberts; A C Gordon; W Hope; P Georgiou; A E G Cass; A H Holmes
Journal:  J Antimicrob Chemother       Date:  2018-04-01       Impact factor: 5.790

9.  Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).

Authors:  Alan Abdulla; Annemieke Dijkstra; Nicole G M Hunfeld; Henrik Endeman; Soma Bahmany; Tim M J Ewoldt; Anouk E Muller; Teun van Gelder; Diederik Gommers; Birgit C P Koch
Journal:  Crit Care       Date:  2020-09-15       Impact factor: 9.097

10.  Dried Plasma Spot Based LC-MS/MS Method for Monitoring of Meropenem in the Blood of Treated Patients.

Authors:  Haiwei Cao; Yi Jiang; Shaomin Wang; Haihuan Cao; Yanyan Li; Jing Huang
Journal:  Molecules       Date:  2022-03-19       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.